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HOW transplantation came to be a clinical discipline can be pieced together by perusing two volumes at 
reminiscences collected by PaulL Terasaki in 1991-
1992 from many of the persons who were directly involved. 
One volume was devoted to the discovery of the major his-
tocompatibility complex (MHC), with particular reference to 
the human leukocyte antigens (HLA) that are widely used to-
day for tissue matching. l The other was focused on mile-
stones in the development of clinical transplantation.2 All the 
contributions described in both volumes can be traced back 
in one way or other to the demonstration more than a half 
century ago by Peter Brian Medawar that the rejection of al-
lografts is an immunological phenomenon.3,4 
Ten years later (1953), Billingham, Brent, and Medawars 
showed that tolerance to skin allografts could be induced by 
inoculating fetal or prenatal mice with immunocompetent 
spleen cells from adult donors. Because of their immunolog-
ical immatunty, the recipients were incapable of rejecting the 
spleen cells whose progeny survived indefinitely. Specific 
nonresponsiveness to donor strain tissues was retained as the 
recipient animals grew to adult life, while normal reactivity 
evolved to third-party grafts and other kinds of antigens. 
This was not the first demonstration that tolerance could 
be deliberately produced. Analogous to the neonatal trans-
plant model, Traub6 showed in 1936 that the lymphocytic 
choriomeningitis virus ILCMV) persisted after transplacental 
illiection of the embryo from the mother, or alternatively by 
In]ection into newborn mice. However, when the mice were 
~ntected as adults, the virus was eliminated immunologically. 
lmllar observations had been made in experimental tumor 
~odelsK Murphy 7 reported in 1912 the outgrowth of Rous 
~ leken sarcoma cells on the chorioallantoic membranes of 
lick or pigeon egg embryos, which could be reversed by in-
OCUlatIOn of auult chicken lymphoid cells 8 whereas sarcoma 
lib 1 . . ' P antatlOn mto adults was not possible. 
the The observations of Murphy and Traub did not influence 
ttl early development of transplantatIOn. Instead, the Impe-
~ and rationale for the experiments of Billingham, Brent, 
an Medawar,5,9 and similar studies in chickens by Hasek !O Ong . , 
mated With Owen, II who demonstrated that freemartin 
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cattle Ithe calf equivalent of human fraternal [dizygotic] 
twins) became permanent hematopoietic chimeras if fusion 
of their placentas existed in utero, allowing fetal cross-circu-
lation (Fig. 61.1); such animals permanently accept each 
other'S skin. I2 Burnet and Fennerl3 predicted that this nat-
ural chimerism and tolerance to other donor tissues and or-
gans could be induced by the kind of experiments success-
fully performed by Billingham, Brent, and Medawar. However, 
Billingham and Brent I4,15 soon learned that in mice, parallel 
with similar observations by Simonsenl6 in chickens, the 
penalty for infusion of immunocompetent hematopoietic 
cells was graft-versus-host disease (GVHD) unless there was 
a close genetic relationship (i.e., histocompatibility) between 
the donor and recipient. 
This discovery was the beginning of modern transplanta-
tion immunology, an extensive history of which has been 
written by Brent,I7 one of its principal architects. Each cell-
and organ-defined branch of transplantation also has had its 
historians, who have described the stages through which spe-
cific kinds of procedures moved to the bedside from experi-
mental laboratories, or in some cases directly. The culmi-
nating clinical events can be capsulized with a list of the first 
successful allotransplantation, in humans, of the kidney, 18 
liver,19 heart,2o,21 lung,22 pancreas,23 intestine,24 multiple ab-
dominal viscera,25 and bone marrow.26- 29 
Although such milestones and dozens of lesser ones are 
important, the emphasis in this account is on developments 
that were applicable to all varieties of allografts and respon-
sible for major transitions in transplantation ideology. It 
will become apparent as the layers of history are peeled away 
that there were only two seminal turning points in the evo-
lution of clinical transplantation. One was the induction of 
chimerism-associated neonatal tolerance by Billmgham, Brent, 
and Medawar in 1953. The second was the demonstration in 
1962-1963 that organ allografts could self-mduce tolerance 
with the aid of immunosuppression. 30 All subsequent devel-
opments in organ transplantation depended on exploitation 
of this principle, using variations of the drug strategy that had 
made its discovery possible. Ironically, the downside of the 
resulting revolution in organ transplantation was the early in-
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FIGURE 61.1. The chimerism in freemartin [fraternal twins) de-
scribed by Owen. ll Cross-tolerance to formed blood elements fol-
lowed intrauterine circulatory exchange in dizygotic twins. Mutual 
tolerance to skin grafts was later proved by Anderson with Medawar 
et a1. 12 [From Starzl TE) Blitz GW JI. Surgical physiology of the trans-
plantation of tissues and organs. By permission of Surg Clin North 
Am 1962;42:55-67.) 
troduction of a conceptual error that distorted the maturation 
of transplantation immunology and also adversely affected 
the orderly development of general immunology. 
The error, which was not corrected until well into the 
199MsIP1~PP was the conclusion by concensus that organ allo-
graft acceptance involved different mechanisms than the 
chimerism-dependent ones of neonatal tolerance and its clin-
ical analogue of bone marrow transplantation. Consequently, 
the vast literature that sprang up in the intervening 30 years 
admirably documented the progression of improvements in 
clinical transplantation while failing to explain what was be-
ing accomplished.34 Therefore, the reader may profit by skip-
ping to the last section of this chapter ("Allograft Acceptance 
Versus Acquired Tolerance") before attempting to understand 
what went on between 1963 and 1993, and before. 
Prehistory: Before Immunosuppression 
An indelible mark on the pages of transplantation history was 
left with the perfection of techniques for organ revascular-
ization by surgical anastomosis in the laboratories of Alexis 
Carrel at the beginning of the twentieth century.35 Aside from 
the technical contributions, which also provided the founda-
tion for conventional vascular surgery, Carrel recognized that 
transplanted organ allografts were not permanently accepted 
although he did not know why. 
Using vascular surgical techniques, animal research in 
transplantation was most highly focused on the kidney for 
most of the next half-century.36-38 The extrarenal vacuum 
rapidly was filled between 1958 and 1960 with the develop-
ment in several laboratories of canine models with which to 
study all the intraabdominaP9--+3 and thoracic organs 4 4-46 AI· 
though each organ presented specific technical and physio-
logical issues, the core problems of immunosuppression! tis· 
sue matching, and allograft preservation eveRtually were 
worked out mainly with the kidney and liver and .' 
other organs with minor modificatlOns. applied to 
Hetero (Xeno) Transplantation 
The first known attempts at clinical renal transplantatio 
vascular anastomoses were made between the begin . n by 
the nineteenth century and 1923 in France,-l7 derman~g of 
elsewhere (summarized by Groth-l9 ) using pig, sheep, gl~t :d 
subhuman primate donors. None of the kidneys funet" d 
. . . loned for long, 1£ at all, and the human reCIpients died a few h 
. Ours 
to 9 days later. No further ammal-to-human transplantat 
were tried again until 1963, after immunosuppression ~ns 
available.50,51 as 
Homo (Allo) Transplantation 
In 1936, Voronoy of Kiev, Russia, reported the transplanta. 
tion of a kidney from a cadaver donor of B+ blood type to a 
recipient of 0+ blood type,52. in violation of what have be-
come accepted rules of tissue transfer53,5-l (Table 61.1). In ad. 
dition, the allograft was jeopardized by the residual risk of 
acute mercury poisoning (from a suicide attempt) that caused 
the recipient's renal failure. A final adverse factor was the 
6-h lapse between the donor's death and organ procurement. 
The allograft did not make any urine during the 48 h of the 
patient's posttransplant survival. Although other attempts 
may have been made by Voronoy,55 another 15 years passed 
before significant kidney transplant activities were resumed 
in France. 
In 1951, Rene Kuss56 and Charles Dubost57 in Paris and 
Marceau Servelle in Creteil,58 carried out a series of renal 
transplantations with kidneys removed from convict donors 
immediately after their execution by guillotine. The next 
year, the French nephrologist, Jean Hamburger) in collabora· 
tion with the urologist Louis Michon at the H6pital Necker 
in Paris, reported the mother-to-son transplantation of a kid· 
ney that functioned well for 3 weeks before being rejected.59 
The procedure developed by Kuss and the other French sur-
geons and used for this first live donor kidney transplanta-
tion has been performed hundreds of thousands of times since 
then. The operation's relative freedom from chronic morbid-
ity would soon be demonstrated with the identlcal(monozy-
gotic) twin transplantations of Joseph E. Murray and John 
TABLE 61.1. Direction of Acceptable Organ Transfer When the 
Donor and Recipient Have Different ABO Red Cell Types. 
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. Boston. 'd 1 I 1 U1 'f bv the: French teams were WI e y <nown, anc 
h et orts. .' f' 1 d f e k d to Pans lD the early 1950s to learn Irst lan t10c e. . 
erience. One ot the observers of the extrapen-
the jexp operation (often called the Kuss procedure in 
pe VIC . 161 d 
. John Merrill, as Hume and MerrIll et a . ' e-t~~eir account of the first clinical trials at the Pe-l; gham Hospital. In Hume's nine Boston cases, how-
" Beg1~ b~t one of the allografts were placed in the recipient 
eftl, al scularized from the femoral vessels, and provided 
'thigh leva k' . 
. ' , ary drainage by s m ureterostomIes, 
WIth hunn ceptional case in the Boston series61 was the first 
fe ex . d' Th donor and recipient operations were periorme III 
one. t eld Massachusetts, on March 30, 1951, by Dr. L.H. SpJ10g Ie , d b f ' little. The donor kidney was excise ecause 0 a carCI-
[)oO 1 the lower ureter, and implanted in the vacated renal ~mao . ~ of the recipient after removal 01 the natIve organ. The 
, ien! patient had been under short-term dialysis care at ~:~nghamI where the first artificial kidney in the United 
States had been brought from Holland by Wilhelm Kolff and 
modified by Harvard engineers, as described in detail by 
, Moore62 
The next eight operations, in which the allografts were 
: placed in the anterior thigh location, were performed by 
, Hume in Boston between Apnl 23, 1951, and December 3, 
1952. The report of the nine cases stands as one of the med-
ical classics of the twentieth century, providing an extensive 
clinical and pathological profile of renal allograft rejection in 
untreated human recipients. The descriptions complemented 
the report of Michon and Hamburger of the live donor French 
case (see earlier59 ) and the pathfinding studies in dogs by the 
Dane, Morten Simonsen,37 and W. James Dempster in Eng-
land38 It is noteworthy that Hume treated some of his pa-
tients with adrenocortical steroids. It was already known from 
expenmental studies that steroid therapy modestly mitigated 
primary skin graft rejection63-<S5 and even slowed the accel-
erated rejection of presensitized recipients. 66 
Although compilation of the Boston series postdated the 
early French efforts ias generously annotated by Hume), the 
commitment of the Harvard group to transplantation was ev-
Ident long before the availability of effective immunosup-
pressIon. Hume, who moved in 1956 from Boston to the Med-
Ical College of Virginia (Richmond), remained a major force 
~ transplantation until his death in the crash of a private 
i9;~e lof which he was the pilot! near Los Angeles in May 
in . HIS fnend and colleague, John Mernll, who remamed 
1 98Boston, drowned off the beach of a Caribbean island in 
4. 
Qr a~one of the European and American efforts to this time, 
ical together, would have had any lasting impact on med-
in PdractIce were it not for what lay ahead. The principal 
gre lents f " , tissue m 0 organ transplantatIOn-ImmunosuppreSSIOn, 
.... erel~tchlrgI and organ procurement (and preservation 1-
rOUli-::;,--'.;.;J;", tt1m p~l un~nown or undeveloped. The only unequivocal 
recipleB' 1954 P e ot chmcally significant allograft function through !-:,: tientslv~p provided by one of the nommmunosuppressed pa-
~ Pomn 0 Hume et aPI whose thigh kIdney produced life-sup-
an-iiJ- tion or unne OUtput ior 5 months. Similar claims about tunc~ ~~~ ;i.e an allogrart transplanted to the orthotopic location(" 
" as tn D I' I, . Con ' 00 Itt es case6 lJ or to a nonanatomical site6H were 
sldered Implausible by later critics. 
The existence of these cases was public knowledge, but 
the failure of all the grafts (usually with death of the patients) 
left very little room for optimism. The perception, if not the 
reality, of hopelessness was changed at the Peter Bent 
Brigham Hospital 2 days before Christmas in 1954, when a 
kidney was removed from a healthy man by the urologist J. 
Hartwell Harrison and transplanted by Joseph E. Murray to 
the pelvic location of the donor's uremic identical twin 
brother.60•69 Although no effort was made to preserve the iso-
graft, it functioned promptly despite 82 min of warm is-
chemia. The recipient lived for nearly 25 years before dying 
of atherosclerotic coronary artery disease . 
According to Merrill et a1.,60 exploitation of genetic iden-
tity for whole-organ transplantation had been suggested by 
the recipient's physician, David C. Miller, or the Public 
Health Service Hospital, Boston. It already was well known 
that identical twins did not reject each other's skin grafts?O 
To ensure identity, reciprocal skin grafting was performed in 
the Boston twins. Although the identical twin cases attracted 
worldwide attention, organ transplantation now had reached 
a dead end. Further progress in the presence of an immuno-
logical barrier would require effective immunosuppression. 
The possibility of meeting this obiective could only be re-
garded as bleak. To understand why, it is necessary to ap-
preciate not only how barren the landscape of immunology 
was, but also how slowly the preexisting information had 
been filled in. 
A century had passed between the first vaccination pro-
cedure in 1796 (Edward Jenner, smallpox) and the confirma-
tion of the immunization principle by Louis Pasteur (with 
chicken cholera and rabies). The proof obtained by Robert 
Koch that microorganisms caused anthrax (1876) and subse-
quently many other infectious diseases stimulated a search 
for the host protective mechanisms. This search yielded com-
ponents of the immune response: antibodies (Emil Adolf von 
Behring and Shibasaburo Kitasato [1890Jl, immune cells (Ilya 
Metchnikoff [1884J), and complement (Jules Bordet [1895J1. In 
addition, Paul Erlich developed the side-chain theory 11890), 
according to which each cell has a vital center of protein sub-
stance and a senes of side chains (later known as receptors) 
to which toxic substances as well as nutrients were absorbed 
and then assimilated. In 1910, Erlich introduced the first an-
timicrobial drug, an arsenical compound effective against 
syphilis, yaws, and several other infections. 
Decades passed between the cluster of great contributions 
at the tum of the twentieth century and the proposal by F. 
McFarlane Burnet that antibodies were produced in each in-
dividual only to those antigens to which he or she was ex-
posed. [3 The lack of major movement between times is eVI-
dent from a list of Nobel Prizes (Table 61.2). Although 6 of 
the first 17 Nobel laureates (1901-1919) were honored for 
work relevant to immunology/transplantation, there was 
only one further example (Karl Landsteiner, ABO blood 
groups) among the next 57 (1920-1959). Beginning with Bur-
net and Medawar, 17 of the 77 laureates since 1960 have been 
directly responsible for, contributed to, or directly benefited 
from advances in transplantation (Table 61.21. 
In Burnet's original hypothesis of immunity, antibody 
synthesis was postulated to occur after an antigen locked on 
to a membrane-bound receptor la version of the antibodv) that 
was displayed at the surface of an immune cell. After bll1d-
ing the antibody, the cell proliferated, producing a clone that 
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TABLE 61.2. Nobel Prizes Related to Immunology/Transplantation. 
1901 
1905 
1908 
1912 
1919 
1930 
1960 
1972 
1980 
1984 
1985 
1987 
1988 
1990 
1996 
Emil Adolf von Behring 
Hemrich Hermann Robert Koch 
Paul Ehrlich 
llya Metchnikoff 
Alexis Carrel 
Jules Bordet 
Karl Landsteiner 
Sir Frank MacFarlane Burnet 
Sir Peter Brian Medawar 
Gerald M. Edelman 
Rodney R. Porter 
Barui Benacerrat 
Jean Dausset 
George Davis Snell 
Niels Kai r erne 
Georges r.F. Kohler 
Cesar Milstein 
Michael Stuart Brown 
Joseph Leonard Goldstein 
Susumu Tonegawa 
Gertrude Belle Elion 
George Herbert Hitchings 
Joseph E. Murray 
E. Donnall Thomas 
Rolf Zinkernagel 
Peter C. Doherty 
"Proved with liver transplantation for indicatlOn oi hyperchoiesteroiemia."9,25o 
secreted identical antibodies (the clonal selection theory). 
Nossal subsequently proved that the clone rose from a single 
cell ("one cell/one antibody")?! Although Burnet's hypothe-
sis was not yet complete, it was to become the cornerstone 
of modem immunology. 
The Concept of Immunosuppression 
With Recipient Cytoablation 
The transition of tissue and organ transplantation from an ex-
~rcise in futility to tenuous practicality involved a surpris-
ngly small number of advances that were interspersed with 
ong periods of frustration. Alter Medawar's demonstration in 
1944 that rejection was an immunological event,3,4 a logical 
md inevitable question was, why not protect the organ allo-
;raft by weakening the immune system? This idea was tested 
n rabbits in 1950-1951 with cortisone63 .64 and total-body iI-
adiation72 Both prolonged skin graft survival for only a few 
ays. 
Neither these results, nor those reported with cortisone 
1 1952 by Cannon and Longmire65 in a chicken skin graft 
lOde!. generated much optimism. However. the Cannon-
ongmire report contained three observations that, in retro-
iect, presaged not only the acquired neonatal tolerance pro-
.Iced by Billingham, Brent, and Medawar the following year, 
Discovery of antibodies 
Cause and effect of microorganisms and infection 
Side-chain (receptor) concept; champion of humoral 
antimicrobial therapy 
Champion of cellular immunity. 
Vascular surgery and transplantation 
Discovery of complement 
Discovered ABO blood group antigens 
Clonal selection hypothesis 
Acquired transplantation tolerance 
Characterized immunoglobulins 
Clanfied structure of antibody molecule 
Discovered immune response genes and 
collaborated in discovery of MHC restriction 
Discovered first HLA antigen 
Discovery of major histocompatibility complex (MHCj gene in .' 
Important immunological hypotheses ~IK 
Hybridoma technology "', . 
Hybridoma technology 
Hepatic control of cholesterol metabolism (With Goldsteinl' 
Discovered somatic recombination of immunological 
receptor genes 
Codiscovery iwith Hitchings) of 6-mercaptopurine (6-MPI and 
azathioprine 
Kidney transplantation 
Bone marrow transplantation 
Codiscovered (with Doherty) the role of MHC 
in adaptive immune response to pathogens 
but also the most important clinical advances in transplan-
tation of the succeeding decades. First, skin grafts exchanged 
between l-day-old chicks of different breeds had a high rate 
of initial engraftment and a 6% incidence of permanent take. 
Second, the window of neonatal opportunity was gone by 4 
days. Third, and most important, the percent of permanent 
engraftment of neonatally transplanted skin was increased to 
more than 20% by a course of cortisone, with no increase of 
mortality. 
The significance of the third observation was recognized 
by Cannon and Longmire, who wrote: "Although the co~D 
sane did not entirely prevent a reaction in the homograft, It 
did decrease the incidence of reaction. Even more importan~ 
the increased incidence of reaction (sic) free grafts appeare 
to maintain itself after the drug was discontinued. This phe-
nomenon is one which up to the present time has not bee~ 
found in homograft experiments on mammals and humans. 
Despite a confirmatory follow-up study in 1957/3 the n~­
glected Cannon-Longmire article faded quickly from the co . 
lective memory of both basic scientists and cliniCians. In co:-
trast, the achievement of acquired neonatal tolerance Y 
Billinbo-ham. Brent, and Medawar in 19535.9 ignited mterest Uld M' an transplantation as never before. Two years later, aln t 
Prehn74 attempted to simulate in adult mice the environrnerr 
that allowed the acquisition of neonatal tolerance. The thr~~ 
steps were first, to cripple the immune system with Rr:~K 
lethal total-body irradiation ITBIJ i next, to replace It Wit 
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marrow (producing a hematolymphopoietic b:; iinally, to engraft skin from the same inbred 
h' donor ot the bone marrow. 
... as t C riments were successful/4 but as in the neona-
.. The exyemodel, lethal GVHD could be avoided only when 
o· ~ rolerance"weak" histocompatibility barriers. 7.0 Applying 
. '... - were . l' d 1'· b I 
. Iller.. . m strategy tor (1 ney transp antatlOn m eag e 
-hnnens . 76 d thee Cooperstown, New York, Manmck et a1. ' reporte 
dog:> In 1 llograft tunctlOn m a supralethally uradiated re-
_vi rena . d 
'P'.¥ hat also was given donor bone marrow an was a 
Clplent It'mphopoietic chimera; the animal lived for 73 days 
hefllat~ \ng of pneumonia. Because it was demonstrated later 
betor~ Y kind of outcome depended on the identity of the dog 
that th l~vte antigens (DLAI, 77,78 an accidental DLA match 
lymP °p~cted in retrospect to have been present in Mannick's 
was SUS ~ 
·ment Efforts by Hume et a1.79 and subsequently by Ra-expen . . 
. t80 and others to broaden the range of acceptable hlS-
;!o:omPJnbilitY inevitably led to lethal GVHD, rejection, 
or borh. 
BoNE MARROW TRANSPLANTATION 
With the impasse, workers in bone marrow and whole-organ 
transplantation took separate pathways. Bone marrow trans-
plantation was dependent a priori on the classic chimerism-
associated acquired tolerance induction defined at the outset 
by Billingham, Brent, and Medawar in the neonatal model. In 
spite of the fact that only highly histocompatible donors could 
be used, clinical success with bone marrow engraftment 
was achieved in 1963 by Mathe et al. in Paris,26 whose pa-
tient lived for 2 years with chronic GVHD before commit-
ting suicide. 
Five years later, Gatti et a1. in Minneapolis28 and Bach et 
al. at the University of Wisconsin,17 each transplanted bone 
marrow to recipients who are well today. The lifetime efforts 
of Thomas,29 van Bekkum,sl and others fueled the matura-
tion of bone marrow transplantation into accepted clinical 
therapy for numerous hematological diseases (including ma-
lignancies), acquired immunodeficiency disorders, mes-
enchymal-based inborn errors of metabolism, and an assort-
ment of other indications. 
Bone marrow transplantation was an intellectual triumph. 
Its development could be traced in a straight line back to the 
experiments of Main and Prehn 74 and before that to the ae-
qUir:d neonatal tolerance of Billingham, Brent, and Meda-
War) 9 and the natural tolerance of Owen's freemartin cattle. ll 
WHOLE-ORGAN TRANSPLANTATION 
In contrast, clinical organ transplantation, which preceded 
bone marrow transplantation by a decade, appeared to be dis-
connected from a rational base when it was concluded that 
organ engraftment seemingly was independent of chimerism. 
An extension of the Mam-Prehn strategy (i.e., lethal TBl fol-
lowed by bone marrow and kidney allografts as in Mannick's 
dog) was used by Murray et al H2 in only 2 cases, both in 1958. 
The next 10 kidney recipients in Boston were conditioned 
with sublethal TBl without bone marrow18,82,B3 Eleven of 
the 12 irradiated patients died after 0 to 28 days. 
The survivor (who was not given bone marrow) had ade-
quate renal function from the time hiS fraternal twin brother's 
kidney was transplanted on January 24, 1959, until he died 
in July 1979 (Table 61.3). With this historical accomplish-
ment, the genetic barrier to organ transplantation had been 
definitively breached for the first time in any species. 18 Five 
months later, Hamburger et a1.84 added a second fraternal 
twin transplantation, using the same treatment (Table 61.3). 
This second recipient had good renal function until his death 
26 years later from carcinoma of the urinary bladder. 
In these two dizygotic twin cases, it was conceivable that 
the donor and recipient placentas had fused dunng gestation, 
analogous to Owen's freemartin cattle (see Fig. 61.1). This sus-
picion was put to rest at the Paris centers of Jean Hamburger85 
and Rene KUSS86 by four more examples during 1960-1962 of 
survival of 1 year or more. In Kuss' two cases, the donors were 
not related (see Table 6l.3). During the critical period from 
January 1959 through the spring of 1962, the cumulative 
French experience was the prinCipal (and perhaps the ody) jus-
tification to continue clinical trials in kidney transplantation. 
The experience from Boston and Paris summarized in 
Table 61.3 showed that bone marrow infusion was not a nec-
essary condition for prolonged survival of kidney allografts 
and ostensibly eliminated the requirement of chimerism. The 
stage was set for drug therapy. In fact, both Hamburger and 
Kuss mentioned the use of adrenal cortical steroids as an ad-
junct to TBI (Table 61.3), but neither the dose, nor the indi-
cation for the steroids, was described. In addition, Kuss sec-
ondarily administered 6-mercaptopurine (6-MP) to one of his 
cytoablated patients as early as August 196086 "on the basis 
of the recent results of the experimental studies conducted 
by CaIne ... "87 (see next section). Calne had made an invited 
visit to the Paris center a few months earlier (Rene Kuss and 
Roy CaIne, personal communication). 
TABLE 61.3. Kidney Transplantation with 6 Months or More Survival as of March 1963. 
Survival 
Cnse City" References Date Donor (months)b 
Boston 18,82,83 1-24-59 Fraternal twin >50 
Paris 84,85 6-}9-59 Frarernal twin >45 
3 Paris 86 6-22-60 UnrelatedC 18 (diedl 
4 Paris 85 12-19-60 MotherC 12 (died) 
Paris 86 3-12-61 UnrelatedC 18 (died) 
6 Paris 18 }-12-62 Cousinc >13 
Boston 83, lOS 4-5-62 Unrelated 10 
"Boston: I.E. Murray Ipatients 1, 7l; Pans: r. Hamburger Ipatlents 2, -t, 6!; R. KU5S ,patIents 3, 51. 
hThe kidneys in patients 1, 2, and 6 tunctioned for 20.5, 25, and 15 years, respectively. Pdtient 7 reiected his graft af-
ter 1'" months and died ~liter return to Jialy:-;is. 
<.;AJlunct sterolu therapy. 
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Some authOlities have considered irradiation-induced and 
drug-induced graft acceptance to be different phenomena.49,83,88 
More recently, it has become obvious that the variable degree 
of graft acceptance achieved with sublethal TEl between Jan-
uary 1959 and February 1962 was fundamentally the same as 
that seen in tens of thousands of drug-treated humans fol-
lowing transplantation of various whole organs (see later, "Al-
lograft Acceptance Versus Acquired Tolerance"). 
With Drug Immunosuppression 
After it was leamed that TEl alone could result in prolongation 
of kidney allografts, it was logical to focus the search for im-
munosuppressive drugs on myelotoxic agents that mimicked 
irradiation. In September 1960, Willard Goodwin of Los An-
geles produced severe bone marrow depression with metho-
trexate and cyclophosphamide in a young female recipient of 
her mother's kidney. The patient subsequently developed sev-
eral rejections that were associated with bone marrow re-
covery. They were temporarily reversed with prednisone sev-
eral times during the 143 days of survival. It was the first 
example of protracted human kidney allograft function with 
drug treatment alone.89 However, the case was not reported 
until 1963. 
was recognized. CaIne and Murray also were fore .....•. 
an earlier climcal experience of .Hopewell, Caine, an~;~edKhyK;:D 
et al., lOJ which was not pubhshed until 1964 in hS\Vick 
MP had been used to treat three kidney recipie~ts (iW tch 6-
one with a live donor) in 1959-1960; all three recipinc Uding 
died. ents had 
Consequently, the canine studies of 6-MP and 
, " aZathiO-pnne 111 Boston were hIghly focused on finding more ff 
tive drug combinations,83,9:i,97,104 Although d e ,ee. 
a renoCOrtIcaj 
steroids were tested, they did not appear to potentiat th 
value of azathioprine,95,97 prompting Murray in his die, ale 
. 1 f d' . h rue tna to opt or a Junct CytotOXiC agents suc as azaserine d 
actinomycin C.83 Only 1 of the first 10 kidney recipiean 
treated with either 6-MP in = 2) or azathioprine-based ~t~ 
munosuppression (n = 8) survive~ for more than 6 mon:s 
(the last entry in Table 61.3),83,100 
At the nadir of the resulting pessimism, two reproducible 
observations, first in dogs and then in humans, were made at 
the University of Colorado. Taken together, these events pro-
foundly shaped future developments in transplantation of all 
organs, and eventually of bone marrow. The observations 
were encapsulated in the title of a report published in Octo-
ber 1963: "The Reversal of Rejection in Human Renal Ho. 
mografts with the Subsequent Development of Homograft 
Tolerance. "30 
The reversal was readily accomplished by temporarily 
adding unprecedented high doses of prednisone (200 mg/day) 
to baseline immunosuppression with azathioprine. The evi-
dence that the live donor kidneys had self-induced tolerance 
under an umbrella of immunosuppression was equally dear. 
Most of the recipients had a subsequent progressively di-
minishing need for immunosuppression, usually to doses 
lower than those that initially failed to prevent rejection. The 
tolerance was complete enough to allow the patients to go 
home to an unrestricted environment, Nine of the first 10 of 
these kidney recipients achieved prolonged graft survival,JO 
including two who bear the longest continuously function-
ing allografts in the world today (more than 35.5 years) and 
have been free from immunosuppression for 32 and 4 years, 
respectively. 106 
The practical as well as theoretical implications of these 
observations were recognized throughout the report: "A state 
of relative immunologic non-reactivity seems to have been 
produced which has lasted for as long as 6 months , .. It is 
not known whether this is due to a change in the antigenic 
properties of the homograft, or to an alteration in the specific 
[host) response to the stimulus of the grafted tissues. The ap-
parent host-graft adaptation does, however, provide some 
hope for prolonged functional survival .. , It would seem prob-
able that the [therapeutic) principles, as defined with the kid-
ney, can eventually be applied to other organ homografts .. ' 
The prior knowledge that a rejection crisis is almost a cer-
tainty and that it usually can be managed by relatively con-
servative means should serve as a deterrent to the excessive 
use of measures that may cause fatal bone marrow depres-
sion .. , It is also conceivable that the avoidance of a primary 
host-graft reaction by these means [excessive Immunosup-
pression) would prevent the adaptive process If ;0 
At the time this bellwether series was comptled between 
the autumn of 1962 and April 1963, the only other active clin-
ical transplantation programs in the United States were In 
Richmond (dnected by David Hume)107 dnd at the Peter Bent 
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. I Therapeutic Dogma of Immunosuppression. E!I1ptrca 
Baseline agents 
" of strategy~ ________________ _ 
. ~ AzathIOprine" 
lin" therapy C 1 . ~ . adjustments yc osponne 
, ' ReDong~lfsone dose, or 
, of pre hoiJ agentsb 
: Jl1ulyITlP . 
, , .w·case trial I 
. CJSc J oren tial eno r 
Tacrolimus 
[;Ill P 
. I wean 109 . . ~hylactiC prednisone. Equivalent results were obtamed with 
'Alone or With m~~mmsteag of azathioprine. l73•ll• 
Jophosphaml . 1/" 11136 
eye , d for praphyiacllc rnductwn. llJUuallv use 
. am Hospital in Boston (directed by Joseph Murray an~ 
Bngh Mernll). 105 The hIstorically important program ot fl~ll d Goodwin at UCLA isee earlier89 ) had been closed be-
Wi ar .. h hIE II the recipients dIed m less t an 5 mont s. n urope, cause a . ' f d 
1 b dy irradiation bneHy remamed the pre erre treatment rota 0 d R 
h long-standing Paris centers of Jean Hamburger an ene Jtt e '. db 
K while Michael Woodrutf of Edmburgh ha egun test-uss, 
h· . 108 ing azat lOpnne. . . 
The results in the Colorado senes, and more Importantly 
an exact description of the strategy that had been used to in-
duce variable degrees of incomplete tolerance (Table 61.4), 
created a surge of new activity. Within 12 months, new kid-
ney transplant centers proliferated in North America, and also 
in Europe. Most of these second-generation programs remain 
in operation today. 
The observations in the original kidney recipients were 
promptly confirmed. However, the proposed explanation for 
these successes (i.e., graft alteration plus loss of specific im-
munological responsiveness)30 was controversial and re-
mained so for the next three decades (see later, "Allograft Ac-
ceptance Versus Acquired Tolerance"). Except for reports 
from the University of Colorado, the term tolerance was stu-
diously avoided from 1964 onward in referring to the long-
surviving dogs and human kidney recipients that had been 
produced by the end of 1963. 
The article most often quoted as contravening tolerance 
was that of Murray et a1.102 despite the fact that, as the au-
thors took pains to make clear, the evidence in their report 
was inconclusive and mvolved only two canine experiments 
of a potentially crucial nature. The two long-surviving dogs 
had been given renal homografts 9 and 18 months previously 
and had been treated for most of these periods with one of 
the purine analogues. Renal function was deteriorating at the 
tIme contralateral kidneys from the original donors were 
t.ransplanted. The second organs were rejected after 23 and 3 
days, respectively, as would be expected. 
In commending Murray's 1964 report and conclusions, 
!VIedawar wrote 109:. "There is, however, something special 
about renal homografts, as [Michaell Woodruff's appraisal in 
thIS volume makes very clear. A synoptic survey of more than 
1,000 renal homografts in dogs carried out by Murray and his 
~lfeagues IMurray, Ross Sheil, Moseley, Knight, McGavic &. 
,al11mlU, 19M I [102] has shown that foreign kidneys do some-
tll11es become acceptable to theH hosts for a reason other than 
acqUired tolerance in the technical sense ... There has been 
;~n~fnaj nurnbt:!rs' I cham:;ed to those of current reference list (this chapteri; 
t: qUOtation IS uthtrwise verbann1. 
an adaptation of some kind ... a possibility Woodruff has long 
urged us not to overlook [110,1111 though there is no reason 
to believe it an antigenic adaptation". 
Medawar continued 109: "One possible explanation is the 
progressive and perhaps very extensive replacement of the 
vascular endothelium of the graft by endothelium ot host ori-
gin, a process that might occur insidiously and imperceptibly 
during a homograft reaction weakened by immunosuppres-
sive drugs ... Another possibility, raised by R.Y. Caine 
(though not mentioned by him in his contribution to this vol-
ume) is the laying down of a protective coat of host antibody 
on the endothelial inner surface of the graft ... an explana-
tion which would classify the phenomenon under the general 
heading of 'enhancement'. " 
These disclaimers notwithstanding, the commonality of 
the rejection barrier for different organs was self-evident. So 
was the likelihood that the means of inducing acceptance of 
one organ could be used for all the others. 112 There also was 
evidence from earlier experiments that a liver allograft could 
protect other donor tissues and organs. It had been noted m 
1962 that intestine and pancreas had very little histopatho-
logical evidence of rejection in untreated canine recipients if 
they were components of multivisceral allografts that also 
included the liver.113 The observations were confirmed 30 
years later in a rat version of the same multivisceral proce-
dures1l4.115 
Most convincingly at an experimental level, it was shown 
in 1964 that orthotopic canine liver allografts could induce 
and maintain their own acceptance far more frequently and 
permanently than renal allografts, even with a treatment 
course of azathioprine as short as 4 months. I 16,117 Soon tllere-
after, spontaneous engraftment was demonstrated after liver 
transplantation in untreated outbred pigs,llB-122 many of 
which passed through self-resolving rejection crises. 121,123.124 
Thus, it already was clear by 1964-1965 that the liver is 
the most tolerogenic organ. In the late 1960s and early 1970s, 
CaIne, Zimmerman, and Kamada formally proved that the 
liver tolerization extended to other donor tissues transplanted 
at the same time or later, first in untreated outbred pigsl25 
and then without immunosuppression in selected rat strain 
combinations.126-128 Although they were important, the ex-
perimental studies with hepatic allografts only affirmed the 
conclusion reached with the 1962-1963 experience in clini-
cal renal transplantation suggesting that all organs were ca-
pable of inducing tolerance. Just as with liver allografts, the 
self-induction of donor-specific tolerance by heart and kidney 
allografts without the aid of immunosuppression was later 
demonstrated by Corry1l9 and Russell l30 in selected mouse 
strain combinations. 
The key mechanism of kidney induced allograft accep-
tance was suggested as early as 1964 to be clonal exhaus-
tion.lJ! This concept was developed more fully for liver al-
lografts in the illustration and caption reproduced in Fig. 61.2, 
published in 1969. 132 Induction of the activated clone by al-
loantigen was depicted via host macrophages rather than by 
antigen-presenting dendnuc cells, which would not be de-
scribed until 1973133 In the text accompanying the figure, it 
was pointed Out that exhaustion and deletion of an antigen-
specific clone had been postulated by Schwartz and 
Dameshek as early as 1959 to be the mechanism of the tol-
erance to heterologous protein induced in rabbits with the aid 
of 6-mercaptopurine.90 In additIOn, Simonsen had suggested 
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FIGURE 61.2. Hypothesis published in 1969 of allograft acceptance 
by clonal exhaustion. Antigen presentation was depicted via the 
macraphages rather than by the dendritic cells (which had not yet 
been described). A gap in this hypothesis was the failure to stipulate 
the 10catlOn of the immune activation. (By permission at Experience 
in Hepatic Transplantation. W.B. Saunders Co., 1969. 132) 
in 1960 that clonal exhaustion induced by allogeneic spleno-
cytes could lead to the acquisition of tolerance in adult ani-
mals in the absence of immunosuppression. 134 
The error of making semantic distinction between toler-
ance and graft acceptance was understandable. The picture 
that had emerged from the remarkable accomplishments with 
clinical kidney transplantation between January 1959 and the 
spring of 1963 was not a product of new insight in immunol-
ogy. Instead, successful organ transplantation was an intel-
lectually troubling and inexplicable violation of the im-
munological rules of the time. The revolution in immunology 
that had already began, and would continue for the next third 
of a century, did little to change this view. 
The Burnet antibody hypothesis of clonal selection Isee 
earlier l3 ) was validated and extended to cellular immunity by 
the late 19505,135-137 but this had minimal influence on the 
clinical development of transplantation; neither did many 
other key advances in immunology that were either contem-
poraneous with, or came after, the rise of organ transplanta-
tion. The role of the thymus in the ontology of the immune 
system and in the postnatal immune function of rodents was 
discovered in 1961 [by Jacques Miller I38,139). However, in hu-
mans thymectomy did not significantly alter either the early 
or late course of kidney transplant recipients. 140, 141 Lympho-
cytes were not formally assigned a function until 1963 (by 
James Gowans 142, 143), although workers in transplantation 
wcre aware several vears earlier that these mononuclear 
leukocytes were the c~llular agents of allograft rejection 144~14S 
IFig. 61.3). By the time the distinction was clearly established 
between T and B lymphocytes, transplantation was an estab-
lished specialty of clinical medicine. 
Thus, the ascension of organ transplantation came as a 
surprise to most immunologists. Even as the clinical advances 
had begun to unfold, Burnet!37 had wntten III the New Eng-
land Journal of Medicme that, " ... much thought has been 
given to ways by which tissues or organs not genetically and 
antigel11cally identical with the patient might be made to sur-
vive and function in the alien enVlronment. On.the whole, 
the present outlook lS highlY unfavorable to success .... ". Pes-
Tissue lwater Electrolytes Lymphocytes Serum proteins 
~ Humoral antibodies 
BK~ I \ ~ 
, '(.----.0 ~----y-*P 
Top view Cross sec tion 
FIGURE 61.3. Schematic representation of diffusion chamber used 
in studies by Algire,144 from which he concluded that lymphocytes 
were the cellular agents of allograft rejection. (From Starzl TE, Butz 
GW Tr. Surgical physiology of the transplantation of tissues and or-
gans. By permission of Surg Clin North Am 1962;42:55-67.) 
simism also was deeply ingrained in conventional practi-
tioners of medicine. Well into the 1960s editorials were pub-
lished in major clinical journals that questioned both the in-
herent feasibility and the ethical basis of transplantation 
procedures. 147 As a consequence, transplantation acquired a 
renegade image, a burden soon compounded by difficulties in 
extending its reach to the replacement of vital organs other 
than the kidney. 
One dilemma, as it was perceived at the time, is shown 
in Figure 61.4.148 It was feared that chronic drug immuno-
suppression powerful enough to prevent organ allograft rejec-
tion would render the recipient hopelessly vulnerable tr: in-
digenous and enviromnental pathogens. Early reports of 
infectious disease complications in the early Colorado recipi-
ents 149 and elsewhere, gave warning that dire consequences 
might, in time, be in store for all recipients. It also was sus-
pected that immune surveillance to tumors would be eroded, 
a possibility that was verified but shown to be manageable by 
19SUK1pM~lpO 
Autopsy studies in failed clinical cases revealed a typical 
pattern. Infections for which specific antibiotics were avail-
able could be largely controlled. However, opportunistic mi-
croorganisms of normally low pathogenicity were overrepre-
sented and appeared at autopsy to be the main cause of 
death. 153 Of these infections, cytomegalovirus (CMVI was the 
Host defense 
Bacteria ~y1Mrklprmmobppflk 
(peak at rejection crisis) Bacteria 
FIGURE 61A. The original legend for thlS iigure was" PI ),sible mech-
anisms of simultaneous loss of host reactivity to spcCllic straWS at 
endogenoLls bacteria, as well as to the alien renal tissue." [By per-
miSSlOTI of Surgery :St. Louis) 1964;56:296.] 
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mon and lethal. The presence of Pneumocystis 
J1Iost con: coinfection with CMVl54 premonitored the lethal 
,rinJl as ,',' . . I AIDS ' 
,<'" .. h's combinanon ot mtecnous agents m t 1e epI-I at t 1 !1l e. . the non transplant population that lay two decades 
deIlllC In 
Jhead. 
The Maturation of Transplantation 
AI hough it was entirely empirical, the practical framework 
t 'red for the maturation of clinical transplantation was es-
re4ulallY complete by the end of 1963. Without knowing ei-
sent! . 
ther the nature of the normal Immune response or the way 
which it had been subverted, It had been learned how to 
;~hablv redirect the immune response with the aid of im-
munosuppression. Surgtcal (see openmg sectIOn) and preser-
vation techniques (see later) had been developed for trans· 
plantation of all the organs; these are used cunently with only 
minor modifications. Yet, the held of organ transplantatlOn 
stalled, and now entered a phase that was euphemistically 
tenned "consolidation." The reason was the failure to find 
improved means of exploiting the principles for control of re-
jection that had been established with azathioprine and pred-
nisone (see Table 61.4). 
Improved Immunosuppression 
ANTILYMPHOID STRATEGIES 
Between 1963 and 1979, the only significant advance in clin-
ical immunosuppression was the introduction in 1966 of het-
erologous antilymphocyte globulin (ALG),155,156 This step 
was a logical extension of Gowan's demonstration of the im-
munosuppressive effects of lymphoid depletion with thoracic 
duct drainage ITDD) in rats 142,143 In fact, Woodruff and An-
derson showed that TDD and antilymphocyte serum (ALS) 
had additive effects. 1S7 
roD was clinically used by Franksson and Blomstrand in 
1963 to treat kidney recipients in Stockholm,15S an approach 
that resurfaced periodically during the next 2 decades (sum-
manzed in [159]). Conditioning with TDD before transplan-
tatIOn clearly reduced the frequency and vigor of kidney re-
lection, but 30 days of pretreatment were required in 
humans, 159,160 compared to the 5 days in Gowan's rats. 142,143 
~weverI the inconvenience, complexity, and expense of 
o precluded its wide use. 160 For the same reasons, total 
lymphoid irradiation ITLI)161 which also was an effective 
means of lymphoid depletion but with the disadvantage of 
n~t being qUlckly reversible, did not have a lasting impact on 
c InJcal transplantation. 162,163 
In COntrast, ALG was a major turning point for two rea-
:ons. First, it was a critical factor in the emergence of ex-
rarenal 0 l' d . d fr rgan transp antatlon. See on ,11 was a prototype rug 
i~m which numerous variations evolved. The concept of mit-
b hng cellular Immunity with heterologous antibodies had 
c:en proposed by Ilya Metnikoff at the end of the nineteenth 
ntury164 d . l' d b d b' 165 d 1 manIoc, an was revlta lze y In er ltzen - 1 an Wa <s-
Iva lli7 before Woodruff and Anderson,157 Levey and Meda· 
r, Monaco, Wood and Russell 168,169 and other surgeons 
recogn' .' I ' In lzed ItS potential role in clinical transplantation. 
!Ym h lUOSt of the animal investigations up to 1963, the anti-
P Ocyte annbodles were raIsed m rabbits and III all cases 
the raw antilymphocyte serum (ALS) was administered. In 
preparation for clinical trials, horse antidog ALS was prepared, 
and the active moiety was refined from the gamma globulin. ISS 
After the product was shown to inhibIt or reverse rejection in 
the canine kidney and liver transplant models,156 comparable 
horse antihuman ALG was produced from the serum of horses 
that had been immunized with leukocytes separated from hu-
man lymphoid organs (lymph nodes, spleen, thymus).l55 
The first clinical trial of ALG began in 1966. Daily injec-
tions were given to kidney recipients for 1 to 4 postoperative 
weeks as a short-term adjunct to continuous azathioprine and 
prednisone. 156 After encouraging results were obtained in the 
kidney trial, liver transplantation was resumed, with long sur-
vival of several patients. The successful liver replacements in 
the summer of 196719 expanded the horizon of transplan-
tation to the other vital extrarenal organs. Within the suc-
ceeding 27 months, heart,20,21 lung,22 and pancreas trans-
plantation23 also was accomplished, using variations of the 
treatment shown in Table 61.4. As had happened with kid-
ney centers in 1963, a wild proliferation of extrarenal (par-
ticularly heart) programs followed. However, almost all them 
closed within the next 2 years, because of an overwhelming 
failure rate. 
Polyclonal ALG was never used in more than about 15% 
of kidney transplant cases reported to registries up to the early 
1980s, in part because it was in no sense a standardized drug 
like azathioprine and prednisone. Although the use by Na-
jarian and Simmons I 70 of known numbers of cultured human 
lymphoblasts for accurately timed horse immunization im-
proved the predictability of the ALG potency, batch·t0-batch 
variations in potency remained problematic. If Antibody ther-
apy" came of age with monoclonal antibodies whose pro-
duction was made feasible by the hybridoma technology of 
Kohler and Milstein. l7l OKT3, the first-generation mono-
clonal antibody was directed at all T lymphocytes. 172 Subse-
quent antibody preparations, which include less immuno-
genic humanized "hybrids," have been directed at discrete 
targets such as T-cell subsets, adhesion molecules, and T-cell 
or interleukin 2 receptors. However, when these agents are 
used, the "induction" strategy has been essentially the same 
as with the original crude ALG. 
CYCLOPHOSPHAMIDE 
While the experience in this middle era, defined by the first 
triple-drug regimen, demonstrated the feasibility of trans-
planting the vital extrarenal organs, it also indicated that fur-
ther progress would require better baseline immunosuppres-
sion. Substitution of the alkylating agent, cyclophosphamide, 
for azathioprine was such an effort. 173 The characteristic cycle 
of immunolOgical confrontation and resolution leading to graft 
acceptance was no different with this drug than with azathio-
prine-based therapy. However, when the results with kidney 
and liver transplantation were almost identical to those using 
azathioprine but at a higher price of complications, the trials 
were discontinued. 174 Although cyclophosphamide thereby be-
came a footnote in the history of organ transplantation, it con-
tinued to playa role in bone marrow transplantation. 
CYCLOSPORINE 
Another decade would pass before the greater potency of cy-
closporine would make transplantation of the liver and other 
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cadaveric organs (including the kidney) a reliable service. Cy-
closponne, an extract from the fungi Cylindrocarpon lucidum 
and Trichoderma polysporum. was discovered by Dreyfuss et 
a1. i75 and charactenzed biochemically by Ruegger et aLi 76 and 
Petcher et al. l77 It was shown to be immunosuppressive by 
Borel et al.178-i80 with multiple test systems including skin 
allotransplantation in mice, rats, and guinea pigs. 
The drug depressed humoral and cellular immunity, and 
had a preferential and quickly reversible action against T lym-
phocytes. Unlike azathioprine and cyclophosphamide, these 
effects were not accompanied by bone marrow depression or 
other prohibitive organ toxicity. The ability of cyclosporine 
to prevent or delay rejection of hearts, kidneys, livers, or pan-
creases was promptly shown in rats, rabbits, dogs, and pigs 
by Kostakis, lSI Calne,182-184 and Green 185 and their associ-
ates. There was no hint in these preclinical studies that 
nephrotoxicity would be the dose-limiting factor in human 
trials. 
The toxicity profile of cyclosporine became evident in 
Caine's initial evaluation of cyclosporine in human recipients 
of 32 kidneys, 2 pancreases, and 2 livers, reported in 1978-
1979186,lB7 The ability of the drug to prevent rejection, alone 
or in combination with myelotoxic drugs, exceeded anything 
previously seen. However, the requisite overdosage caused 
multiple serious side effects: nephrotoxicity, neurotoxicity, 
diabetogenicity, a 10% incidence of B-cell lymphoma, and 
cosmetic changes (gingival hyperplasia, facial brutalization, 
and hirsutism). 
When cyclosporine in lower doses was combined with 
prednisone in the treatment algorithm shown in Table 61.4, 
the prognosis of cadaver kidney recipients was improved,188 
and transplantation of the liver,189 heart,190,191 and lungs 192 
was brought to the level of a practical clinical service. Reca-
pitulating the aborted avalanche of 1967, many new ex-
trarenal programs appeared, joining the five extant liver cen-
ters (Denver [from 1963], Cambridge [1968], Hannover [1972], 
Paris [1974], and Groningen [1977]), and the single remaining 
heart program (Stanford [from 1968]). This time, most of the 
programs flourished. 
TACROLIMUS 
Cyclosporine was the unchallenged baseline immunosup-
pressant for all varieties of transplantation until it was shown 
in 1989 that intractably rejecting liver allografts could be reg-
ularly rescued by replacing cyclosporine with tacrolimus, 193 
an extract of Streptomyces tsukubaensis discovered by Kino 
et al. 194 Tacrolimus was tested initially in a rat cardiac trans-
plant model by Ochiai et al.,195 and soon thereafter by Murase 
et al. in rats 196,197 and by Todo et al. in dogs 198,199 and sub-
human pnmates. 199,200 
In addition to numerous confirmatory reports of its abil-
ity to rescue about 75 % of intractably rejecting human liver 
allografts,201 tacrolimus could salvage an equal proportion of 
rejecting hearts, kidneys, and other organs.202 In virtually all 
such cases, a switch back to cyclosporine was never made. 
Consequently, clinical trials using tacrolimus primarily were 
begun.202-204 
By early 1990, more than 150 liver, kidney, heart, and 
heart-lung recipients had been treated from the time of trans-
plantation with immunosuppression based on tacrolimus 
rather than cyclosporine,:w5 It was learned from this experi-
TABLE 61.5. Nonirnrnunological Profile. 
FK 506 
--------------------------------------------_____ CM Nephrotoxicity + +., ----
++ 
Neurotoxicity + + 
Diabetogenicity + + 
Growth effects 
Hirsutism 
Gingival hyperplasia 
Facial brutalization 
Hepatotrophlc effects 
Gynecomastia 
Other metabolic effects 
o 
o 
o 
++++ 
o 
+++ 
++ 
+ 
+++ 
+ 
Cholesterol increase Ob + + 
Uric acid increase +? ------------------------------------------~---~ 
All effects dose related; + + + +, worst. 
'Less hypertenSIon. 
bIn rats, Van Thiel has shown an increase in cholesterol synthesis and serum 
conCentratIOn. 
Source: Transplantation Proceedings 1991 ;23:914-919. 
ence that the three major side effects of the drug (nephro-
toxicity, neurotoxicity, and diabetogenicity) were comparable 
to cyclosporine. Hypertension and hyperlipidemia were less 
than in historical cyclosporine controls. The cosmetic effects 
of cyclosporine were not seen (Table 61.5). 
The effective use of both cyclosporine and tacrolimus re-
quired the same pattern recognition and therapeutic response 
that have guided organ transplantation since its inception Isee 
Table 61.4). The dose ceilings of the four widely us~d base· 
line immunosuppressants were imposed by toxicity: myelo-
toxicity for azathioprine and cyclophosphamide, and the more 
complex side effects shown in Table 61.5 for cyclosporine and 
tacrolimus. The dose floors were revealed by the break-
through of rejection. Because none of the four drugs could be 
used alone, they had to be incorporated into "cocktails" in 
which the requisite doses of the individual drug constituents 
were determined on a case-to-case basis by trial and error. 
Dose-maneuverable prednisone has remained a constant for 
36 years, but steroid dependence declined with the more po· 
tent baseline agents. 
The lead organ for azathioprine was the kidney. The de-
velopmental responsibility for cyclosporine was shared by the 
kidney and liver, while the liver bore the principal burden for 
tacrolimus. 193,201,203,205-209 However, progress with one kind 
of organ atlograft inevitably meant progress for all. Thus, sur-
vival of each kind of organ graft rose in the same three dis-
tinct leaps between 1962 and 1998 (Fig. 61.5). With tacro-
limus, the intestine was no longer a "forbidden" organDO-212 
The Ripple Effect 
ORGAN PROCUREMENT AND PRESERVATION 
The sudden arrival of clinical kidney transplantation in 
1962-1963 was so unexpected that little collateral research 
or other formal preparation had been made to preserve organs. 
Although kidneys were successfully transplanted in the plO-
neer identical twin cases despite protracted periods ot warm 
ischemIa, the maturation of clinical transplantatlOn could not 
proceed without effective organ conservation. This was aC-
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fiGURE 61.5. The three eras of orthotopic liver transplantation at 
Iheuruversities of Colorado (1963-1980) and Pittsburgh (1981-19931, 
defined by azathioprine iAZA), cyclosporine ICYAI, and FK 506 
lucrolirnusl-based iTACI immunosuppression. The same stepwise 
improvement was seen with all organs. Top: Patient survival. Bot-
tom: Graft survival. These results were about 10% lower than pa-
tient survival in both the cyclosporine (1980-1989) and tacrolimus 
eru11989-1993! because of effective retransplantation, an option that 
did not exist previously. 
complished at first with total body hypothermia of living vol-
unteer kidney donors,213 using methods developed by cardiac 
surgeons for open-heart operations.2l4 In the experimental 
laboratory, Lillehei et al,39 simply immersed the excised in-
testine in iced saline before its autotransplantation, a method 
:lso used by Shumway in developing experimental and clin-
ICal heart and heart-lung transplantation.4446 Thus, the prin-
:le of hypothermia was understood at an early time, al-
ough i: was not efficiently applied. 
The hrst major innovation in hypothermia was in the lab-
l?~ryI when canine liver allografts were cooled by infusion 
°h C llled fluids into the vascular bed of hepatic allografts via ~ e POrtal vein.42 Before this time, survival of dogs after liver 
ansp antation was almost never obtained while afterward 
~cess became routine. In a logical extensi;n to clinical kid-
infu transplantation, the practice was introduced in 1963 of 
!lex SIng chilled lactated Ringer's or low molecular weight atel~a~ solutlons into renal artery of kidney grafts immedi-
Tater then removaPlS 
vatio oday, intravascular cooling is the first step in the preser-
1ll0Stn tot all whole 0. rgan grafts. For cadaver donors, this is 
o ten do . SCnbed b ne In SitU bY,some variant of the techniq,ue de-
COntinu y MarchlOro et al.- l6 lFig. 61.6). ThIS method tor the 
kidney OUs hypothermic perfUSIOn of cadaveric livers and 
brain 'ds w~s used clinically long before the acceptance of 
and Beeat ; Ackerman and SnelF17 and Merkel, Jonasson, 
rgan"' 8 !lavers W h' populanzed the simpler core cooling of ca 
aorta. It cold electrolyte solutions infused into the distal 
/~K 
( A 
B 
FIGURE 61.6. Technique of extracorporeal perfUSion with a heart-
lung machine described by MarchioroIl6 Catheters are inserted via 
the femoral vessels into the aorta and vena cava as soon as possible 
after death. The extracorporeal circuit is primed with a glucose or 
electrolyte solution to which procaine and heparin are added. The ca-
daver is thus anticoagulated with the first surge of the pump. Tem-
perature control is provided by the heart exchanger. Cross-clamping 
the thoracic aorta limits perfusion to the lower part of the body. IBy 
permission of Experience in Renal Transplantation, W.B. Saunders 
Co., 1964.215 ) 
ORGAN PROCUREMENT 
Until 1981, transplantation of the extrarenal organs was an 
unusual event. By late 1981, however, it had become obvious 
that liver and thoracic organ transplant procedures were go-
ing to be widely used. A method of multiple organ procure-
ment was required by which the kidneys, liver, heart, and 
lungs or various combinations of these organs could be re-
moved without jeopardizing any of the individual organs. 
"Flexible techniques" were developed2l9,22o which were 
quickly adopted worldwide. With the methods, all organs to 
be transplanted are cooled in situ, rapidly removed in a blood-
less field, and dissected on a back table. The sharing of or-
gans from a common donor by recipient teams from widely 
separated centers became routine by the mid-1980s. 
Ex VIVO PERFUSION 
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ber components by Belzer et a1. 22-1 resulted in satisfactory kid-
ney preservation for as long as 2 to 3 days. The asanguinous 
perfusion technique eventually was abandoned in most kid-
ney transplant centers when it was learned that the quality 
of 2-day preservation was not better than with the simpler 
"slush" methods Isee following). Nevertheless, it is expected 
that refinement of perfusion technology will someday permit 
tme organ banking. 
"SLUSH" PRESERVATION 
With the so-called static methods, fluids of differing osmotic, 
oncotic, and electrolyte composition are infused into the 
allograft beiore placing it in a refrigerated container.22s,226 
The solution described by Collins, Bravo-Shugarman, and 
Terasaki225 (which resembles intracellular electrolyte con-
centrations), or modifications of it, were used for almost two 
decades. Renal allograft preservation was feasible for 1 to 2 
days, long enough to allow tissue matching and sharing of or-
gans over a wide geographic area. Experiments with hepatic 
allografts by Benichou et al227 using the Collins-Terasaki so-
lution and by Wall et ap28 with the plasma-like Schalm so-
lution led directly to liver sharing between cities, but with a 
time limitation of only 6 to 8 h. 
The introduction for liver transplantation of the Univer-
sity of Wisconsin IUW) solution by Belzer, Jamieson, and 
Kalayoglu,229,23o was the first major development in static 
preservation since the Collins-Terasaki solution,231 The su-
periority of the UW solution for preservation of the kidney 
and other organs was promptly demonstrated in experimen-
tal models and confirmed in clinical trials232-237 The UW 
preservation doubled or tripled the time of safe preservation 
Jf the various allografts, making national and international 
;haring of most organs an economical and practical objective, 
rhe Life Sciences 
Nhile occupying its own unique niche, transplantation has 
lrawn from and in tum enriched all the other basic and clin-
cal scientific disciplines, Aside from changing the philoso-
lhy by which organ-defined specialtIes of surgery and medi-
ine are practiced, transplantation grew parallel with, and 
:ontributed in a major way to, advances in immunology, phar-
nacology, oncology (e,g., the role of tumor immune surveil-
ance I52,238J, infectious disease, intensive care, and anesthe-
iology. Study of each of the different kinds of allografts has 
ielded an organ-specific harvest of special information. Ex-
mples include a better understanding of diabetes mellitus 
lith pancreas transplantation and of the effects of denerva-
,on on cardiopulmonary function with heart and lung trans-
lantation. 
The liver became the key organ in unmasking the secrets 
f acquired tolerance because of its large content of im-
lUnocompetent leukocytes Isee earlier, and "Allograft Ac-
;ptance versus Acquired Tolerance"). In addition, the func-
onal complexity of the liver as well as its metabolic 
lteractions with other abdominal viscera have made hepatic 
ansplantation a "mother lode" for physiological studies,239 
In the course of determining the optimal revascularization 
. auxiliarv 11 vers transplanted to ectopic sites or to the nor-
al location,42,2+0,241 it was found that endogenous insulin is 
liver growth iactor,2412-l3 the first such hepatotrophic factor 
be identifled, Using transplantation-denved models, a fam-
ily of other molecules was delineated with insulin-like h 
totrophic properties 244 Eventually the gene was disc epa_ 
oVered 
that expresses one of these (augmenter of liver reg , 
tion)245-147 The hepatotrophic factors, most of which enera. 
are cy 
tokines (e.g., hepatocyte growth factors [HGF]J, regulate I' . 
size, stmcture, regeneration, and metabolic homeostasis lVe{ 
Studies of hepatotrophic physiology led directly or' d' 
rectly to liver replacement for cure of more than two dln 1-
hepatic-based inborn errors of metabolismI14K~ inclrdinoz~n 
milia I hypercholesterolemia.249,25o The role of hepatic t; a-
plantation in first suggestll1g, and then proving, that the l~ns-
. IVer 
governs cholesterol metabolism has been described el 
where 238,249-251 Elucidation of the cellular and molecu~e­
mechanisms was rewarded by bestowal of the 1985 kob~ 
Prize to Brown and Goldstein Isee Table 61.2) e 
Immunological Screening 
The importance of the genetically determined major histo-
compatibility complex IMHC) in determining the immune reo 
sponse to allografts was evident from investigations by 
George Snell in inbred mice,252 which in tum derived from 
the work of Peter Gorer (see "the seminal influence of Gorer 
and Snell"253). However, the information was not clinically 
applicable. Thus, immunological screening of donors and re-
cipients was not done during the volatile developmental pe-
riod of 1959-1963. 1 The possibility of tissue matching did not 
begin to emerge until the discovery by Dausset of the first 
human leukocyte antigen (HLA) in 1958,254 and the discov-
ery in the same year by Van Rood et a1. 255 of antileukocyte 
antibodies Isoon shown to be HLA directed) in the sera of 
pregnant women. 
The report in 1964 by Terasaki256 of the microcytotoxic· 
ity test, with which HLA antigens could be detected sero-
logically in minute quantities of sera, was a critical develop-
ment in moving forward with the classification of the 
antigens. 
The Crossmatch Principle 
As it turned out, the greatest impact of pretransplant tissue 
matching has been the prevention of hyperacute rejection by 
observation of ABO compatibility guidelines and the routine 
use of the cytotoxicity cross match. 
ABO COMPATIBILITY 
Hyperacute rejection was first observed more than 30 years 
ago when ABO-mismatched renal allografts were transplanted 
into patients who had preformed antigraft ABO isoagglu-
tinins.53,257 After kidneys were lost on the operating table, ar· 
teriograms of the infarcted organs showed nonfilling of the 
small vessels, correlating histopathologically with wide-
spread thrombotic occlusion of the microvasculature. It was 
concluded that high-affinity isoagglutinins in the recipienJ 
sera had bound to A or B antigens in the graft vessels and 
parenchymal cells. This finding was consistent wIth rapl 
changes in reCipient isoagglutinin titers that followed organ 
revascularization. The guidehnes formulated from this expe-
rience53 ,257 were designed to avoid such antibody confronta-
tions Isee Table 6U). , cis 
The ..'iliO rules also apply to heart, liver, and other kin 
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nsplantation. As was originally observed in 1963 
aforgan ~~~isrnatched kidneys, however: 53,257 not all organs 
\\1th All he hostile envIronment of antlgratt Isoagglutmms 
placed ~n t arne fate. In fact, the longest continuously func-
meet t e Sal allograft in the world!06 is a B+ kidney donated 
ti011tng re~U_year_old A -r male recipient by his younger sis-
!O a thJen- "ry 31 1963. In addition, it was learned at an early 11 anUa' , . 
tef 0 hat the liver is more resIstant to antibody attack than 
timE t 'os 
her organs. -, . . .. . 
ot h'srocompatiblhty studIes m which human volunteers 
In e~sitized with purified A and B blood group antigens, 
were 5 d' f' I" R 
. variably increase tIters 0 lsoagg utmms, apaport 
caustng d h (h' f)' et aJ.259 showed accelerate or yperacute w Ite gra t re)ec-
, f ABO-incompatlble skm grafts transplanted to reClpl-
uon 0 . h ' 1 f with high titers. ThIS result completed t e CITC e 0 ev-
entS . f 'b d' h ,.. 
d nee indicating antlgra t antI 0 les as t e preclpitatlllg Ie. . 
cause of hyperacute organ re)ectlOn. 
WITH NON-ABO ANTIBODIES 
In 1965, hyperacute rejection of a kidney by an ABO-com-
patible recipient was reported for the first time by Terasaki 
et a].260 Terasaki's observation that the serum of the recipi-
ent of a live donor kidney contained preformed antigraft lym-
phocytotoxic antIbodies was promptly confirmed in similar 
cases by Kissmeyer-Nielsen et a1.261 and others,262,263 The ev-
idence of a cause-and-effect relationship in the single first case 
was so clear that Terasaki recommended and immediately in-
troduced his now universally applied lymphocytotoxic cross-
match tes t. 260.264 
It has been shown in presensitized animals and humans 
that antibodies, clotting factors, and formed blood elements 
were rapidly cleared by the hyperacutely rejecting grafts.265,266 
Local fibrinolysis from the renal vein also was a consistent 
finding, and in exceptional cases, there were systemic co-
agulopathies with disseminated intravascular coagulation 
IDIC)267,268 The findings are comparable to those in the 
Arthus reaction, inverse anaphylaxis, generalized Shwartzman 
reaction, and other models of innate immunity.263,267,268 
Non-HLA antibodies such as antivascular endothelial cell 
antibodies also have been associated with hyperacute or ac-
celerated re)ection.269.27o The vulnerability of extrarenal or-
gans to this kind of rejection was ultimately demonstrated 
experimentallyOT1~OTP and clinically. Although the liver was 
the most antibody resistant,2S8 it too was placed at increased 
nsk by the presensitized state274 Hyperacute rejection also 
has been documented in a small number of human organ re-
CIpients in the absence of detectable antibodies. 263 ,275 
TiSsue Matching 
~stor~callvI it was predicted tissue matching would have to 
pertected If long-term engrattment of tissues and organs 
Was to SUcceed with any degree of reliability and predictabil-
Ity, The prophecy was immediately fulfilled with bone mar-
row transplantation, in which anything less than a perfect or 
near-perfect match between the donor and recipient resulted 
~n CVBD or rejection of the graftKOS~19 When similar expec-
t:tlons Were not met in studies by Paul Terasaki in kidney 
ansplant recipients the results initially were treated as a 
SClentlfl'C d 1 'U"'" h hId 1 b scan a .- n,_" W en eater was prove to lave 
i;en correct, TerasakI emerged as the father of HLA match-
g and as an endunng symbol of integrity. Ii. _____ 
Terasaki's investigations began with a retrospective study 
of the influence of HLA matching on the quality of outcome 
of patients bearing long-surviving kidney allografts,lls fol-
lowed by a prospective trial in live donor kidney recipients 
treated with azathioprine and prednisone, with or without ad-
junct ALG.279 Consistent with the results in the classic skin 
graft investigations in nonimmunosuppressed healthy volun-
teers by Rapaport and Dausset, OUM~OUO HLA-matched allografts 
had the best survival and function, least dependence on main-
tenance prednisone, and fewest histopathological abnormali-
ties in routine 2-year postoperative biopsies.283 Unexpectedly, 
however, a cumulative adverse effect of mismatching in the 
kidney recipients could not be identified. 
The equally imprecise prognostic discrimination of HLA 
matching in cadaver kidney transplant cases also was first 
recognized by Terasaki (with Mickey et aJ.284), and has been 
evident in analyses up to the present time. With the large 
sample sizes in United Network for Organ Sharing IUNOS) 
and European databases, virtually every comparison of the dif-
ferent levels of mismatching showed statistical significance. 
However, the absence of a large or consistent matching effect 
unless there is a perfect or near perfect match has always been 
the same. In a recent study of more than 30,000 UNOS pa-
tients for whom optimal matches had been sought prospec-
tively, approximately 85% of the cases were in the two- to 
five-HLA-mismatch spectrum where I-year survival was clus-
tered within 3%. Subsequent half-life projections thereafter 
were in the narrow spread of 9 to 11 years.28S 
Terasaki's conclusions nearly three decades ago breathed 
life into the still struggling fields of liver, heart, and lung 
transplantation. It was a relief to know that the selection of 
donors with random tissue matching would not result in an 
intolerable penalty. A quarter of a century passed before it 
could be explained why HLA matching was critical for bone 
marrow, but not organ, transplantation (see next section)_ 
Allograft Acceptance Versus 
Acquired Tolerance 
During the Festschrift at Harvard honoring Paul Russell's re-
tirement in late November 1990, Norman Shumway told me 
and Leslie Brent about his text on Thoracic Transplantation 
for which he wanted two chapters: one explaining the classic 
immunological tolerance exemplified by bone marrow trans-
plantation, and the other defining the presumably different 
mechanisms of whole-organ allograft acceptance. On learning 
that I thought the two were the same in principle, Shumway 
assigned me to the task of defending this opinion.1H6 
Evidence was obtained first from investigation of long-
surviving human liver, kidney, and other organ reclpi-
ents,31.32,287-289 and then from detailed confirmatory animal 
studiesO9M~O9P The observation that all 30 patients tested had 
low level (micro-) chimerism conformed perfectly with the 
hypothesis being tested that allograft acceptance involved not 
only chimerism, but a bidirectional immune reaction (Fig. 
61.71. The relative strengths of the opposing immune reac-
tions following organ transplantation were simply the reverse 
of those following bone marrow transplantation to the cy-
toablated recipient (summarized in [33,1061). With this para-
digm, it has been possible to view the historical milestones 
of clinical organ as well as bone marrow transplantation in a 
coherent way.34 
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Immune 
Reaction 
Time after Transplantation 
FIGURE 61.7. Contemporaneous host-versus-graft iHVGj and graft-
versus-host (GVHj reactions in the two-way paradigm of transplan-
tation immunology. Following the initial interaction, the mainte-
nance of nonreactivity of each leukocyte population to the other is 
seen as a predominantly low-grade stimulatory state that may wax 
and wane. 
Historically, an organ allograft had been envisioned as de-
fenseless and vulnerable to immunological attack in propor-
tion to its histoincompatibility IFig. 61.8, top left). The same 
dogma in reverse Ii. e., the host was the defenseless target) was 
the conventional view of bone marrow transplantation IFig. 
61.8, top right). Only two pioneer workers raised objections 
to the definition of transplantation immunology in terms of 
a unidirectional immune reaction. In 1960--1961, Simonsen,I34 
and then Michie, Woodruff, and Zeiss,294 postulated that the 
two populations of immune cells in neonatally tolerant mice 
managed to coexist in a stable state by becoming mutually 
nonreactive while retaining the ability to function collabora-
tively Ii. e., in a joint immune response to infection). 
Although this heretical suggestion resembled the concept 
summarized in Figures. 61. 7 through 61.11, the Simonsen-
Woodruff hypothesis was recanted in 1962,295 ostensibly be-
cause no experimental support could be found for it. More 
importantly, however, it had been advanced in a n 
tive climate in whIch "group think" had already tu~n~cepK· . 
difterent direction. For the next 30 years, transplantati~n ~l 
munity and tolerance were conceived as products of tIll-
rectional immune reactions ot the kind that could be s:U.di.· 
in vitro by one-way mixed lymphocyte culture techniq died 
scribed by Bain and Lowenstein"% and B.ach and eirschh~~ ~ 
After chlmensm was dIscovered morgan recipie .. 
1992-1993,31-33 it was recognized that the interaction :~s Ul 
coexisting donor and recipient leukocyte populations Was ~e 
common factor that underlay both the "acceptance" ind e 
by whole-organ allografts (Fig. 61.8, bottom left) and therc~ 
erance induced with bone marrow (Fig. 61.8, bottom ri;' 
This context closed the 30-year intellectual gap between t~~ 
fields of organ and bone marrow transplantation. lrganKas~ 
sOClated chlmensm then co~ld be old~~tghed in a Continuum 
of classIc tolerance models oIffI1S1I~9o-~ll be<>innl'n . h 
' b g Wit the 
original observations by Owen in freemartin cattle IFig. 61.91. 
Organ Engraftment 
The immunocompetent donor leukocytes in organ trans. 
plantation are highly immunogenic multilineage "passenger 
leukocytes" of bone marrow origin (including stem and den-
dritic cells) that migrate preferentially to host lymphoid or-
gans and are replaced in the graft by host cells. The result is 
widespread antigen-specific immune activation of the coex. 
isting donor and recipient cells, each by the other, which pro-
ceeds in successful cases to variable reciprocal clonal ex· 
haustion and then deletion IFig. 61. 7). 
Engraftment under clinical circumstances requires an um· 
brella of immunosuppression to prevent one cell population 
from destroying the other, but in some experimental models 
it occurs spontaneously le.g., after pig liver transplantation 
and in many rodent models). The "nullification" of the two 
a=s explains the poor prognostic value of HLA matching for 
One-Way Paradigm (Organ) One-Way Paradigm (Bone Marrow) 
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FIGURE 61.8. Top panels. One-way para- d 
digm in which transplantatIOn is conceIve 
as involving a unidirectional immune reac' 
tion. Ie it, host-versus-graft (HVGI with VBI 
whole oraans· right araft-versus-host IG 
with bon~ m~rrow ~; other lymphopoietiC 
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digm in which transplantatIOn is seen as 
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.,";.",,,, 
Martinez/Good 
Parabiosis 
(1960) 
i 
Billingham/Brent 
Medawar 
(1953) 
Slavin/Strober (1977) 
Iidstad/Sachs (1984) 
Thomas (1987) 
Organ Tx 
(1992) 
FIGURE 61.9. Continuum of chimerism from observations of Ray 
Owen in freemartin cattle to the discovery m 1992 of rmcTO-
chimerism in organ reCipients. 
organ versus bone marrow t.ransplantation (Table 61.6), and 
the low incidence of GVH disease (GVHD) followmg the en-
graftment in noncytoablated recipients of immunologically 
active organs, such as the intestine and liver. 
In addition to inducing clonal activation and exhaustion 
by trafficking to host lymphoid organs, donor leukocytes that 
survive the initial destructive immune reaction migrate sec-
ondarily to nonlymphoid areas, where they do not generate 
an immune response ("immune indifference"). From here 
they may "leak" periodically to the host lymphoid organs and 
mamtain clonal exhaustion. With clonal exhaustion/deletion 
and immune indifference in combination, both of which are 
regulated by the migration and localization of the antigen,33 
the four interrelated events shown schematically in Figure 
61.10 must occur close together to have organ engraftment: 
double acute clonal exhaustion, maintenance clonal exhaus-
tion, which frequently waxes and wanes, and loss of graft 
immunogenicity as the organ is depleted of its passenger 
leukocytes. 
Bone Marrow Tolerance 
Pretransplant cytoablation renders the recipient susceptible 
to immune attack by donor immune cells ii.e., GVHD), con-
trol of which frequently becomes the principal objective of 
Immunosuppression, rather than the prevention of rejection 
Isee Table 61.6). Because complete destruction of host leuko-
!A:LE 61.6. Differences Between Conventional Bone Marrow ~an Transplantation. 
Bone marrow Organ 
~-----------------------------------~--------
Critical 
~ Recipient cytoablation"..... No 
<- MHC compatibility ~ GVf.rD Not critical 
- Pnncipal complication ~ Rejection 
- Drug-free state ~ Rare Common 
TrJlera ~ - Term for success ~ "Acceptance"b 
\Ote' All ,.... . .. "Dblish~s . ultterences derive trom this theropeutic step, wh1eb m eUect es-
Cf)unten' d.n unopposed GVH reactlOn in the bone marrow reCIpIent whose 
:Or' allf~g Imml.lnL: reaCtion is elImlnated. 
I1peratlOnal ~fF ierJnce." 
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Time 
FIGURE 61.10. The four events that occur in close temporal ap-
prOlamation when there is successful organ engraftment. Top. dou-
ble acute clonal exhaustion (1, 2) and subsequent maintenance clonal 
exhaustion [31 plus Ibottomlloss of organ immunogenicity caused by 
depletion of the graft's passenger leukocytes [41. 
cytes is not possible with conventional doses of cytoabla-
tion,301 the remaining cells will stimulate an alloresponse by 
mature or maturing donor T cells. Nevertheless, under im-
munosuppressive treatment, a weak host-versus-graft reac-
tion mounted by these few recipient cells and a parallel graft-
versus-host reaction mounted by the donor bone marrow cells 
may eventually result in reciprocal tolerance by deletion. 
These processes represent a mirror image of the events after 
organ transplantation [see Fig. 61.8, bottom right). 
Relation to Infectious Disease 
NONCYTOPATHIC MICROORGANISMS 
Early workers in transplantation302,303 recognized the resem-
blance of allograft rejection to the response against infections 
associated with delayed hypersensitivity, exemplified by tu-
berculosis. With the demonstration of the major histocom-
patibility complex- [MHC-) restricted mechanisms of adap-
tive infectious immunity by Doherty and Zinkemagel in 
1973,304-307 it became obvious that allograft rejection must 
be the physiological equivalent of the response to this kind 
of infection. Microorganisms that generate such an adapuve 
immune response are generally intracellular and have no or 
low cytopathic qualities.308 
Although MHC-restricted host cytolytic T lymphocytes 
recognize only infected cells, elimination of all the infected 
cells could disable or even kill the host. Consequently, mech-
anisms have evolved that can temper or terminate the im-
mune response, allowing both host and pathogen to sur-
vive 308,309 These are the same two mechamsms that allow 
survival of allografts (Le., clonal exhaustion/deletion and im-
mune indifference),33 both of which are governed by antigen 
migration and localization.33,308,309 However, unlike the com-
plex dual immune response of transplantation, infectious 1m-
mumty is essentially a host-versus-pathogen reaction. 
The analogies between transplantation and an mfection 
with disseminated noncytopathic microorganisms can be ex-
emplified by the common hepatitis vil1.lses, as shown in 
Figure 61.1133.308.309 The pathogen (antigen I load may rapidly 
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of immune response) 
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FIGURE 61.11. Variable outcomes after infection with widelv dis-
,eminated noncytopathic viruses (or other microorganismsi and 
malogies lin the text below the horizontal axes) to organ and bone 
ncrease during the so-called latent period, but then be dra-
natlcally and efficiently controlled by antigen-specific effec-
or T cells, which then subside (left panel). The transplant a-
ion analogues are acute irreversible rejection (or intractable 
;VHD). Alternatively, a continuously high antigen load with 
n antigen-specific immunological collapse (second panel) is 
:J.uivalent to unqualified acceptance of an allograft. 
Between these two extremes, the persistence of both the 
lfectious agent and a strong immune response results in se-
aus immunopathology le.g., chronic active hepatitis with a 
or C virus infection) comparable to chronic rejection after 
ver transplantation (third panel), or, uncommonly, GVHD. 
'Ie conditions in the cytoablated bone marrow recipient 
imic those of an infection by microorganisms (e.g., rabies 
.d wart viruses) that avoid immune activation by not mi-
ltmg through or to host lymphoid organs lright panel).33 
Because immunity and tolerance to alloantigens follow 
e same rules as the response to nancytopathic microorgan-
ns,33 it is not possible with current transplantation prac-
es to induce tolerance to allografts on the one hand with-
t risking unwanted tolerance to pathogens on the other. In 
s context, the historical anxiety depicted in Figure 61.4 
s correct. 
TOPATHIC MlCROORGANISMS 
~re is no MHC-restricted safety valve for cytopathic mi-
Jrganisms, which are typically extracellular and generate 
full resources of the innate as well as the adaptive im-
ne system308,309 An uncontrollable innate immune re-
nse involving the effectors shown in Table 61. 7 is pro-
ed by discordant xenografts expressing the Gal a Gal 
• E 61.7. Effectors Involved in Response to Cytopathic 
si tes and Discordant Xenografts. 
first line of defense 
'erferons 
\crophages 
mma/delta T cells 
turdl killer iNK! cells 
ells 
pecific or less specific efiectors 
mplement 
I y interleukins 
tgocytes 
TIM E 
Chronic graft rejection 
(or GVHO) 
V Unopposed 
(Immunologically 
Ignored) 
Warts, Papillomas 
in keratinocytes 
Leukocyte depletion: 
ofallogrart 
of recipient (cytoablation) 
marrow transplantation. Horizontal axis. time; vertical aXIS . aJ 
load (v. solid line! and host immune response IJR, dashed 1in~fsy! 
epitope, an epitope that also is found on numerous cytopathic 
bacteria, protozoa, and viruses. 
The clinical use of such discordant animal donors will re-
quire changing the xenogeneic epitope to one that mimics a 
noncytopathic profile, or else elimination of the epitope.310 
Although chimpanzees and baboons do not express the Gal 
antigen, the clinical xenografts transplanted from these sub-
human primate donors in 196350,51 ultimately were damaged 
by an uncontrollable innate immune reaction, dominated by 
complement activation. Similar innate immune mechanisms 
were recognized in the 19605 to be responsible for the hyper-
acute destruction of ABO·incompatible allografts, or allografts 
transplanted to presensitized recipients Isee earlier,263-268). 
Self-N onself-Discrimination 
Survival in a hostile environment requires the ability to 
mount a protective immune response while avoiding a reac-
tion of the immune system against self. Transplantation has 
succeeded because it has not lethally eroded this capability, 
which depends ultimately on the governance of immunolog-
ical responsiveness or unresponsiveness by migration and 10· 
calization of antigen.33 Because the fetus possesses very early 
T-cell immune function,311-313 the ontogeny of self-nonself· 
discrimination during fetal development can be explained by 
the same mechanisms as acquired tolerance in later life, Au' 
toimmune diseases then reflect unacceptable postnatal per· 
turbations of the prenatally established localization of self· 
antigens in nonlymphoid versus lymphoid compartments33 
Conclusion 
The lesson described in this chapter has been learned many 
times before: all knowledge can be traced to its roots, and ul· 
timately to a seed. For clinical transplantation, the histoncal 
beginning was Medawar's recognition that rejection isan f~· 
mune reacnon. Only two pnmary roots sprang trom thiS see . 
One was the demonstration by Billingham, Brent, and Meda-
war in 1953 that tolerance could be acquired by producing stem 
cell-dnven hematolymphopoietic chimerism5; this concept ul-
timately led to bone marrow transplantation in humans. , 
The other root was the demonstration during 1962-1960 
that kidney allografts could consistently self-induce tolerance 
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aid of immunosuppression30; all further develop-
,.1tb the [gan transplantation were derivative from this dis-
"dlentS, laq~e assumption reached by concensus in the early 
CIlrmthat the twO roots reflected different immune mecha-
1960s 1 d to inadequate explanations of organ allograft ae-
(I15lD' e and clouded the meaning of successful bone mar-
_epwnce , 
• , nsplantanon. 
"'I' tra ' h' h I b d 
IV The false assumption, w IC prompt y ecame. ogma, 
dl d succeeding generatIons of SCIentlsts and chmClans 
sad he context that precluded the synthesis of a clarifying 
l\'It ;11 principle of immunology which could be applied to 
centra . Ai 
all transplant, much less nomransplant,. cIrcumstances.. ter 
, . discovered in 1992 that organ reClpients had persIstent 
It was . 'bl h . I 
. ochimerism, It was POSS! e to see t e essentIa com-~a , 
onality of organ and bone marrow transplantatlon, to relate 
~ erYltions after these procedures to the immune response 
o :niectious diseases and neoplasms, and to explain the gen-
:~ip of self-nonself discrimination. 
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